Posts Tagged ‘innovation’

Semaglutide SELECT Study: No News Is News

August 4, 2022 — Sometimes the hardest news to digest is no news. This was certainly the case yesterday for Novo Nordisk, the market leader in anti-obesity medicines. Their stock dropped by nearly 13 percent when the company told investors that there would be no news on the semaglutide SELECT study. So why was no news seemingly such big […]

YWM Engage: Bias Meets the Future in Obesity

July 16, 2022 — On the first full day of YWM Engage, it was plain that this was a different sort of convention for OAC. It was smaller. The group was being very cautious because this rotten pandemic, though it’s less of a threat, isn’t over. So the agenda got right down to the business of bringing everyone up […]

Semaglutide for NASH: Disappointing Results

July 2, 2022 — Nonalcoholic steatohepatitis – NASH – has yet again handed drug researchers disappointing results, this time in a study of semaglutide. Researchers presented this phase 2 study at the International Liver Congress in London last weekend. The whole point of a phase 2 study is to see if a drug works for a specific purpose. On […]

What Does a New Era of Obesity Care Look Like?

June 24, 2022 — For decades now, Lee Kaplan and Caroline Apovian have led what was known as the Blackburn Course in Obesity Medicine every year at Harvard in June. This year, the name of the course has changed to Obesity Treatment 2022. It has moved to the Dartmouth Geisel School of Medicine, where Richard Rothstein has joined Kaplan […]

The Imperative for Progress in Pediatric Obesity Care

June 23, 2022 — It is, quite simply, inspiring to spend an entire day with with a team of people dedicated to doing nothing but advancing the care of young persons living with obesity. We had this privilege yesterday at the University of Minnesota Center for Pediatric Obesity Medicine (CPOM). These are people dedicating themselves to bringing progress to […]

Tirzepatide Data Signal a New Era in Obesity Treatment

June 5, 2022 — This is what you might call a clean sweep. At the Scientific Sessions of the ADA and in NEJM yesterday, researchers unveiled detailed data on tirzepatide for obesity. When Lilly gave us a peek at these data a month ago, “Wow!” was our response. With the full details in view and peer reviewed, we tend […]

Will Plant-Based Meats Save the Planet and Our Health?

May 31, 2022 — Hope springs eternal. Hype sells better than mere facts. Imagined benefits are better than objective documentation. Thus, plant-based ultra-processed foods that simulate the experience of eating meat are still enjoying a health and environmental halo. But will these plant-based meats actually help to save the planet and our health? The Big Plant-Based Health Halo In […]

FDA Approves “An Important Advance,” Tirzepatide

May 14, 2022 — Yesterday, FDA approved tirzepatide for type 2 diabetes, calling it “an important advance.” The brand name will be Mounjaro. This is the same drug for which its maker, Eli Lilly and Company, announced remarkable results in a phase 3 obesity study barely two weeks ago. It is the first of its kind – a dual […]

Why Is Semaglutide More Expensive for Obesity?

May 12, 2022 — Somehow this doesn’t seem right. The list price for for a month’s supply of semaglutide when it’s for diabetes is $892. No matter whether you need a dose of 1 mg, or the new high dose of 2 mg, the price is the same. It goes under the brand name of Ozempic and comes from […]

ECO2022: Obesity Hype, Hope, and Progress

May 6, 2022 — As we prepare to put a bow on ECO2022, it’s plain that some things in obesity are changing rapidly. But others are not. Though the reality of coping with it is still far from ideal, the options are getting much better. The scientific understanding of it has grown sharper, but messages to the public aren’t […]